Patents by Inventor Petra Rietschel

Petra Rietschel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING NON-SMALL CELL LUNG CANCER USING MESENCHYMAL EPITHELIAL TRANSITION FACTOR (MET)-TARGETED AGENTS
    Publication number: 20240084041
    Abstract: The present disclosure provides methods for treating or inhibiting the growth of MET associated non-small cell lung cancer comprising selecting a subject with cancer and administering a therapeutically effective amount of a MET x MET bispecific antibody where each binding arm of the bispecific antibody interacts with a different MET epitope. In certain embodiments, the cancer harbors a MET alteration such as an exon 14 alteration in DNA or a deletion that leads to exon 14 skipping, a MET gene amplification, or MET protein overexpression.
    Type: Application
    Filed: August 31, 2023
    Publication date: March 14, 2024
    Inventors: Javier PEREZ, Petra RIETSCHEL, Mario Antonio NAVAS, Anita BOYAPATI
  • Anti-PD-1 antibodies for treatment of lung cancer
    Patent number: 11926668
    Abstract: The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., lung cancer). The methods of the present invention comprise administering a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody), to a subject with lung cancer wherein the cancer tissue expresses PD-L1.
    Type: Grant
    Filed: February 28, 2022
    Date of Patent: March 12, 2024
    Assignee: Regeneron Pharmaceuticals Inc.
    Inventors: Petra Rietschel, Israel Lowy
  • ANTI-PD-1 ANTIBODIES FOR TREATMENT OF LUNG CANCER
    Publication number: 20220281979
    Abstract: The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., lung cancer). The methods of the present invention comprise administering a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody), to a subject with lung cancer wherein the cancer tissue expresses PD-L1.
    Type: Application
    Filed: February 28, 2022
    Publication date: September 8, 2022
    Inventors: Petra Rietschel, Israel Lowy
  • Anti-PD-1 antibodies for treatment of lung cancer
    Patent number: 11292842
    Abstract: The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., lung cancer). The methods of the present invention comprise administering a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody), to a subject with lung cancer wherein the cancer tissue expresses PD-L1.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: April 5, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Petra Rietschel, Israel Lowy
  • ANTI-PD-1 ANTIBODIES FOR TREATMENT OF LUNG CANCER
    Publication number: 20200010550
    Abstract: The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., lung cancer). The methods of the present invention comprise administering a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody), to a subject with lung cancer wherein the cancer tissue expresses PD-L1.
    Type: Application
    Filed: February 20, 2018
    Publication date: January 9, 2020
    Inventors: Petra Rietschel, Israel Lowy